Cryoport Inc (CYRX) 3.10 $CYRX Cryoport Supports

New Post Public Reply Private Reply Replies (0) Message Board

Sep 12, 2015 at 9:27 AM

Cryoport Inc (CYRX) 3.10 $CYRX

Cryoport Supports Stemedica's Ischemic-Tolerant Stem Cell Product Lines
PR Newswire - Tue Aug 18, 7:30AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"

, the leading provider of advanced cryogenic logistics solutions for the life sciences industry, today announced that its validated cryogenic logistics solution is supporting the worldwide distribution of Stemedica's ischemic-tolerant stem cell product lines.
CYRX: 3.10 (+0.01)

Cryoport Reports 53% Revenue Growth for the First Quarter of Fiscal Year 2016
PR Newswire - Thu Aug 06, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX) today announced financial results for the three-month period ended June 30, 2015.
CYRX: 3.10 (+0.01)

Cryoport to Report First Quarter Fiscal 2016 Financial Results
PR Newswire - Mon Aug 03, 7:30AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"

, a leading global provider of high-quality biological material to the scientific community.
CYRX: 3.10 (+0.01)

Cryoport Completes $6.8 Million Equity Capital Raise
PR Newswire - Wed Jul 29, 12:30PM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"

under a registered public offering. The gross proceeds to Cryoport from the offering, including the partial exercise of the over-allotment option, were approximately $6.8 million, before underwriting discounts and commissions and other offering expenses.
CYRX: 3.10 (+0.01)

Cryoport's Portfolio of Temperature-Managed Clinical Programs Expands to 45 Trials
PR Newswire - Mon Jul 27, 7:30AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"

, the leading provider of advanced cryogenic logistics solutions for the life sciences industry, with markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, is now supporting approximately 45 clinical trials. The majority of these trials are regenerative therapies, including an array of CAR T-cell therapies. In total, these immunotherapy trials are expected to contribute as much as $150 million of revenue for Cryoport over the next five years.
CYRX: 3.10 (+0.01)

Cryoport Announces Pricing of Public Offering of Units and Listing on NASDAQ
PR Newswire - Thu Jul 23, 7:41PM CDT
Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"

, the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced the pricing of an underwritten public offering of 2,000,000 units at an offering price of $3.25 per unit, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock. The common stock and the warrants are immediately separable, and will trade on The Nasdaq Capital Market under the symbols CYRX, and CYRXW, respectively. The warrants will have a per share exercise price of $3.57, are exercisable immediately and will expire five years from the date of issuance.
CYRX: 3.10 (+0.01)

ZenBio Engages Cryoport to Support Distribution of its Human Cell-Based Products
PR Newswire - Tue Jul 14, 7:30AM CDT
Cryoport, Inc. (OTCBB: CYRX) ("Cryoport" or the "Company"

in the distribution of its Human Platelet Lysate as well as its entire array of cell-based solutions for the discovery and development of regenerative therapies.
CYRX: 3.10 (+0.01)

Cryoport Selected for Logistics Support of CaRE Arthritis Personalized Medicine Efforts
PR Newswire - Wed Jun 17, 7:30AM CDT
Cryoport, Inc. (OTCBB: CYRX) ("Company"

.
CYRX: 3.10 (+0.01)

Cryoport: A Niche Player That Doesn't Know It
Gains on Gains - at Seeking Alpha - Mon Jun 15, 3:00PM CDT

CYRX: 3.10 (+0.01)

Cryoport Selected by Lynden International as the Preferred Cryogenic Logistics Provider
PR Newswire - Wed Jun 10, 7:30AM CDT
Cryoport, Inc. (OTCBB: CYRX) ("Company"

as its preferred provider to support cold chain clinical trial logistics for underrepresented diseases in Africa.
CYRX: 3.10 (+0.01)

Cryoport Supports ArunA Biomedical's Cryogenic Shipments of Stem Cell Kits
PR Newswire - Wed Jun 03, 7:30AM CDT
Cryoport, Inc. (OTCBB: CYRX) ("Company"

cryogenic shipments of stem cell kits.
CYRX: 3.10 (+0.01)

Cryoport achieves record revenue rise of 48% for fiscal 2015
M2 - Wed May 20, 6:25AM CDT
Cryogenic logistics company Cryoport (OTCBB:CYRX) disclosed on Tuesday that it recorded a net loss of USD12.2m (USD2.44 per common share) for the 12 month periods ended 31 March 2015.
CYRX: 3.10 (+0.01)

Cryoport Reports Record Revenues For Fourth Quarter and Fiscal Year 2015
PR Newswire - Tue May 19, 7:30AM CDT
Cryoport, Inc. (OTCBB: CYRX) today announced financial results for the three and twelve-month periods ended March 31, 2015.
CYRX: 3.10 (+0.01)

Cryoport to Present its FY2015 Results and Business Update at the 2015 Marcum MicroCap Conference
PR Newswire - Thu May 07, 7:30AM CDT
Cryoport, Inc. (OTCBB: CYRX) ("Company"

, the leading provider of advanced cryogenic logistics solutions for the life sciences industry, today announced that the Company has further established its cryogenic logistics solutions within the animal husbandry market by signing a new customer agreement with Yancey Farms to support the shipment of equine semen for artificial insemination of top German Sport horse Stallions.
CYRX: 3.10 (+0.01)

Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA
PR Newswire - Tue Apr 21, 7:30AM CDT
Cryoport, Inc. (OTCBB: CYRX) ("Company"

, the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers and reproductive medicine, today announced that Dr. Mark W. Sawicki, Chief Commercial Officer, will present at the 3rd Annual BioLogistics Summit in San Francisco, CA on Wednesday, July 15th, 2015, at 2:15 p.m. PT. Dr. Sawicki will discuss advanced logistics for both clinical samples and commercial finished goods of emerging cell and gene therapies.
CYRX: 3.10 (+0.01)

Cryoport Expands Logistics Support to Capricor's DYNAMIC Clinical Trial for Heart Failure
PR Newswire - Tue Apr 07, 7:30AM CDT
Cryoport, Inc. (OTCBB: CYRX) ("Company"

to provide a comprehensive cryogenic logistics solution to support both their ALLSTAR and DYNAMIC clinical trials.
CAPR: 4.03 (+0.02), CYRX: 3.10 (+0.01)

Cryoport has Been Engaged by Roslin Cells for Logistics Support of Roslin's iPSC service
PR Newswire - Tue Mar 31, 7:30AM CDT
Cryoport, Inc. (OTCBB: CYRX) ("Company"

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

EFICYENT Ventures to Connect at Singapore FinTech Fest

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...